K filing that it received a letter from the staff of the Securities and Exchange Commission’s Division of Enforcement in ...

Hims & Hers Health is facing existential risk as regulatory uncertainty and margin erosion undermine its growth narrative. Click here to read why HIMS is a Sell.

The telehealth platform logged a quarterly profit of $20.6 million as it worked to offer a wider range of treatments and grew ...

Hims & Hers Health, Inc., faces GLP-1 headwinds, volatility, and regulatory risk but has strong revenue growth and global ...

Hims & Hers Health has a lower P/E than the aggregate P/E of 84.35 of the Health Care Providers & Services industry. Ideally, one might believe that the stock might perform worse than its peers, but ...

By Nell Mackenzie and Samuel Indyk LONDON, Feb 13 (Reuters) - Hedge fund bets against Hims & Hers Health hit their highest in ...

Hims & Hers Health (NASDAQ: HIMS) has had among the worst runs of any public company over the last year. And, there is little reason to think it will recover. The stock is down 47% in the previous ...

Hims & Hers Returns to the Big Game with a Message to All Americans: The Era of Health as a Luxury is Over New national spot “Rich People Live Longer” exposes America’s economically-driven health gap, ...

Financial giants have made a conspicuous bullish move on Hims & Hers Health. Our analysis of options history for Hims & Hers Health (NYSE:HIMS) revealed 16 unusual trades. Delving into the details, we ...